|
1
|
Pennathur A, Gibson MK, Jobe BA and
Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Paul S and Altorki N: Induction therapy
for esophageal cancer. Thorac Surg Clin. 23:499–507. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sukari A, Nagasaka M, Al-Hadidi A and Lum
LG: Cancer Immunology and Immunotherapy. Anticancer Res.
36:5593–5606. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Palucka K and Banchereau J: Cancer
immunotherapy via dendritic cells. Nat Rev Cancer. 12:265–277.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kantoff PW, Higano CS, Shore ND, Berger
ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims
RB, et al: Sipuleucel-T immunotherapy for castration-resistant
prostate cancer. N Engl J Med. 363:411–422. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cheever MA, Allison JP, Ferris AS, Finn
OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL,
Weiner LM and Matrisian LM: The prioritization of cancer antigens:
A national cancer institute pilot project for the acceleration of
translational research. Clin Cancer Res. 15:5323–5337. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Oji Y, Yano M, Nakano Y, Abeno S,
Nakatsuka S, Ikeba A, Yasuda T, Fujiwara Y, Takiguchi S, Yamamoto
H, et al: Overexpression of the Wilms' tumor gene WT1 in esophageal
cancer. Anticancer Res. 24:3103–3108. 2004.PubMed/NCBI
|
|
9
|
Miyatake T, Ueda Y, Morimoto A, Enomoto T,
Nishida S, Shirakata T, Oka Y, Tsuboi A, Oji Y, Hosen N, et al: WT1
peptide immunotherapy for gynecologic malignancies resistant to
conventional therapies: A phase II trial. J Cancer Res Clin Oncol.
139:457–463. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ohno S, Okuyama R, Aruga A, Sugiyama H and
Yamamoto M: Phase I trial of Wilms' tumor 1 (WT1) peptide vaccine
with GM-CSF or CpG in patients with solid malignancy. Anticancer
Res. 32:2263–2269. 2012.PubMed/NCBI
|
|
11
|
Tsuboi A, Oka Y, Udaka K, Murakami M,
Masuda T, Nakano A, Nakajima H, Yasukawa M, Hiraki A, Oji Y, et al:
Enhanced induction of human WT1-specific cytotoxic T lymphocytes
with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.
Cancer Immunol Immunother. 51:614–620. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mayanagi S, Kitago M, Sakurai T, Matsuda
T, Fujita T, Higuchi H, Taguchi J, Takeuchi H, Itano O, Aiura K, et
al: Phase I pilot study of Wilms tumor gene 1 peptide-pulsed
dendritic cell vaccination combined with gemcitabine in pancreatic
cancer. Cancer Sci. 106:397–406. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kuwano H, Nishimura Y, Oyama T, Kato H,
Kitagawa Y, Kusano M, Shimada H, Takiuchi H, Toh Y, Doki Y, et al:
Guidelines for diagnosis and treatment of carcinoma of the
esophagus April 2012 edited by the Japan esophageal society.
Esophagus. 12:1–30. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Muro K, Hamaguchi T, Ohtsu A, Boku N, Chin
K, Hyodo I, Fujita H, Takiyama W and Ohtsu T: A phase II study of
single-agent docetaxel in patients with metastatic esophageal
cancer. Ann Oncol. 15:955–959. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Garnett CT, Schlom J and Hodge JW:
Combination of docetaxel and recombinant vaccine enhances T-cell
responses and antitumor activity: Effects of docetaxel on immune
enhancement. Clin Cancer Res. 14:3536–3544. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sundstedt A, Celander M, Ohman MW,
Forsberg G and Hedlund G: Immunotherapy with tumor-targeted
superantigens (TTS) in combination with docetaxel results in
synergistic anti-tumor effects. Int Immunopharmacol. 9:1063–1070.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kodumudi KN, Woan K, Gilvary DL, Sahakian
E, Wei S and Djeu JY: A novel chemoimmunomodulating property of
docetaxel: Suppression of myeloid-derived suppressor cells in tumor
bearers. Clin Cancer Res. 16:4583–4594. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kimura Y, Tsukada J, Tomoda T, Takahashi
H, Imai K, Shimamura K, Sunamura M, Yonemitsu Y, Shimodaira S,
Koido S, et al: Clinical and immunologic evaluation of dendritic
cell-based immunotherapy in combination with gemcitabine and/or S-1
in patients with advanced pancreatic carcinoma. Pancreas.
41:195–205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Figdor CG, de Vries IJ, Lesterhuis WJ and
Melief CJ: Dendritic cell immunotherapy: Mapping the way. Nat Med.
10:475–480. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ohnishi M, Sakurai T, Heike Y, Yamazaki R,
Kanda Y, Takaue Y, Mizoguchi H and Kawakami Y: Evaluation of
cytomegalovirus-specific T-cell reconstitution in patients after
various allogeneic haematopoietic stem cell transplantation using
interferon-gamma-enzyme-linked immunospot and human leucocyte
antigen tetramer assays with an immunodominant T-cell epitope. Br J
Haematol. 131:472–479. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kuwana M, Okazaki Y, Kaburaki J and Ikeda
Y: Detection of circulating B cells secreting platelet-specific
autoantibody is useful in the diagnosis of autoimmune
thrombocytopenia. Am J Med. 114:322–325. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Palucka K and Banchereau J: Cancer
immunotherapy via dendritic cells. Nat Rev Cancer. 12:265–277.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu X, Song N, Liu Y, Liu Y, Li J, Ding J
and Tong Z: Efficient induction of anti-tumor immune response in
esophageal squamous cell carcinoma via dendritic cells expressing
MAGE-A3 and CALR antigens. Cell Immunol. 295:77–82. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Narita M, Kanda T, Abe T, Uchiyama T,
Iwafuchi M, Zheng Z, Liu A, Kaifu T, Kosugi S, Minagawa M, et al:
Immune responses in patients with esophageal cancer treated with
SART1 peptide-pulsed dendritic cell vaccine. Int J Oncol.
46:1699–1709. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Forghanifard MM, Gholamin M, Moaven O,
Farshchian M, Ghahraman M, Aledavood A and Abbaszadegan MR:
Neoantigen in esophageal squamous cell carcinoma for dendritic
cell-based cancer vaccine development. Med Oncol. 31:1912014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fujiwara S, Wada H, Miyata H, Kawada J,
Kawabata R, Nishikawa H, Gnjatic S, Sedrak C, Sato E, Nakamura Y,
et al: Clinical trial of the intratumoral administration of labeled
DC combined with systemic chemotherapy for esophageal cancer. J
Immunother. 35:513–521. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Koido S, Homma S, Okamoto M, Takakura K,
Mori M, Yoshizaki S, Tsukinaga S, Odahara S, Koyama S, Imazu H, et
al: Treatment with chemotherapy and dendritic cells pulsed with
multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted
epitopes for pancreatic cancer. Clin Cancer Res. 20:4228–4239.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee JH, Lee Y, Lee M, Heo MK, Song JS, Kim
KH, Lee H, Yi NJ, Lee KW, Suh KS, et al: A phase I/IIa study of
adjuvant immunotherapy with tumour antigen-pulsed dendritic cells
in patients with hepatocellular carcinoma. Br J Cancer.
113:1666–1676. 2015. View Article : Google Scholar : PubMed/NCBI
|
